NCT04102345

Brief Summary

In this pragmatic, clinical study the investigators propose that lavender aromatherapy is comparable to Zolpidem (Ambien) in improving the quality of diagnostic sleep studies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P50-P75 for early_phase_1

Timeline
Completed

Started Sep 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 4, 2019

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

September 23, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 25, 2019

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 10, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 10, 2020

Completed
4 months until next milestone

Results Posted

Study results publicly available

February 24, 2021

Completed
Last Updated

March 17, 2021

Status Verified

April 1, 2020

Enrollment Period

1.2 years

First QC Date

September 23, 2019

Results QC Date

January 19, 2021

Last Update Submit

February 24, 2021

Conditions

Keywords

aromatherapydiagnostic sleep studyzolpidem

Outcome Measures

Primary Outcomes (1)

  • Sleep Efficiency

    Percentage of total time in bed actually spent in sleep. It is calculated as sum of Stage N1, Stage N2, Stage N3, and REM sleep, divided by the total time in bed and multiplied by 100. A higher percentage is indicative of more efficient sleep.

    1 day

Secondary Outcomes (2)

  • Number of Participants With A Successful Polysomnogram (PSG)

    1 day

  • Wake After Sleep Onset (WASO)

    1 day

Other Outcomes (5)

  • Total Sleep Time (TST)

    1 day

  • Sleep Onset Latency

    1 day

  • Rapid Eye Movement (REM) Sleep Onset Latency

    1 day

  • +2 more other outcomes

Study Arms (2)

Lavender

EXPERIMENTAL

1-2 drops of Lavender (essential oil) in approximately 120 ml of distilled water is added to a diffuser 10 minutes before light out. The diffuser runs for approximately 2 hours before automatically being shut off. A low mist option is used on the diffuser.

Other: Lavender Aromatherapy

Zolpidem

ACTIVE COMPARATOR

Pre-prescribed, physician directed use of zolpidem. There is no dose exclusionary criteria for the zolpidem. This study does not have any dose specifications, anyone on zolpidem may be eligible.

Drug: Zolpidem

Interventions

Commercially available lavender essential oil and diffuser.

Lavender

Physician directed, pre-prescribed. Study team does not prescribe zolpidem.

Also known as: Ambien
Zolpidem

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age \>=18 years
  • In-center diagnostic or split night sleep study (PSG)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Regions Hospital Sleep Center

Maplewood, Minnesota, 55109, United States

Location

MeSH Terms

Interventions

Zolpidem

Intervention Hierarchy (Ancestors)

PyridinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Results Point of Contact

Title
Bhavani Kashyap, MBBS, PhD
Organization
HealthPartners Neuroscience Research

Study Officials

  • Charlene E McEvoy, MD, MPH

    Medical Director, Regions Hospital/HealthPartners Sleep Center

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: Non-randomized, pragmatic, clinical study.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 23, 2019

First Posted

September 25, 2019

Study Start

September 4, 2019

Primary Completion

November 10, 2020

Study Completion

November 10, 2020

Last Updated

March 17, 2021

Results First Posted

February 24, 2021

Record last verified: 2020-04

Data Sharing

IPD Sharing
Will not share

There are no plans to share individual participant data (IPD).

Locations